GHRP-6: research, legal status and who sells it
This page is information, not medical advice. GHRP-6 is not approved as a medicine in the markets below unless stated. We don't publish dosing or usage instructions.
- Also known as
- GHRP 6
- Category
- Synthetic growth hormone-releasing peptide
- Evidence level
- Early human trials
- Price range
- $1.50/mg to $10.00/mg, median $4.60/mg across 23 vendors (compare)
- Our lab tests
- None yet (how testing will work)
Legal and regulatory status
| Where | Status |
|---|---|
| United States | Not FDA-approved; FDA lists GHRP-6 in Category 3 for pharmacy compounding and in Category 2 (significant safety risks) for outsourcing facilities [1][2][3]. |
| United Kingdom | No UK-licensed medicine containing GHRP-6 appears in the MHRA products database [4]. |
| European Union | No medicine containing GHRP-6 is authorized in the EU, according to EMA's central and Article 57 product data [5][6]. |
| Canada | No product containing GHRP-6 appears in Health Canada's Drug Product Database [7]. |
| Australia | Schedule 4 (prescription-only) in Australia's Poisons Standard, with possession without authority prohibited under Appendix D [8]. |
| Sport (WADA) | Named as a prohibited GH-releasing peptide under S2 [9]. |
We haven't published a full overview of GHRP-6 yet. The legal status table and live prices on this page are current.
GHRP-6 prices: cheapest listings
The five lowest $/mg listings out of 32. See all GHRP-6 prices
| Vendor | Transparency | Product | Size | Price | $/mg | Stock | Vendor's page |
|---|---|---|---|---|---|---|---|
| Bulk Peptide Supply | 57 | 10 mg | $15 | $1.50/mg | View | ||
| Bulk Peptide Wholesale | 45 | 10 mg × 10 | $150 | $1.50/mg | View | ||
| Chimera Peptides | 27 | 5 mg × 10 | $78 | $1.56/mg | View | ||
| Nationwide Peptides | 85 | 10 mg | $30 | $3.00/mg | View | ||
| Injectify | 32 | 5 mg | $19 | $3.80/mg | View |
Sources
- Drugs@FDA: FDA-Approved Drugs (database searched by active ingredient). U.S. Food and Drug Administration. Accessed Oct 14, 2026
- 503A Categories Update for May 2026: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. U.S. Food and Drug Administration. Accessed Oct 14, 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). U.S. Food and Drug Administration. Accessed Oct 14, 2026
- MHRA Products: licensed-medicine search for "ghrp-6". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
- EMA medicines data: centrally authorised human medicines (export of 14 October 2026). European Medicines Agency. Accessed Oct 14, 2026
- EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 14, 2026
- Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 14, 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 14, 2026
- World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 14, 2026